decisionhealth Newsletters, Part B News - 2001 Issue 3 (March)
Calcium drug reimbursement targeted by some in Congress
Subscribe or sign in to view the full article.
Article Overview
This article covers a Medicare reimbursement issue involving calcium drugs used in dialysis-related care and a proposed congressional response. It also discusses broader policy questions about how Medicare pays for physician-administered drugs, including references to agency oversight, reimbursement benchmarks, and variation among carriers. The piece is relevant to coders, billing staff, compliance professionals, and health policy readers tracking Medicare drug-payment changes and legislation.
Why This Topic Matters
The topic matters because reimbursement policy can affect provider payment, beneficiary drug access, and Medicare spending. It also sits within a wider policy debate over drug pricing benchmarks, self-administered drug coverage, and uniformity in carrier payment practices.
What You Will Learn
- The Medicare reimbursement issue discussed in connection with calcium drugs used in dialysis care.
- The general policy arguments behind the proposed legislative change.
- How the article places the issue within broader debates over physician-administered drug payment methods.
- Which federal bodies and congressional actors are involved in the discussion.
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Compliance professionals
- Healthcare administrators
- Health policy analysts
- Nephrology practice staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com